








# Cancer NEXT 2024

A Unique Platform for Basic Scientists, Cinicians & Industries

30th November 2024, Nizam's Institute of Medical Sciences (NIMS), Hyderabad





The Cancer NEXT 2024 brings together leading researchers, clinicians, and industry professionals to address the critical challenges and opportunities in cancer treatment, with a special focus on the Indian context. As cancer continues to be a major health concern worldwide, this conference aims to foster collaboration, share cutting-edge research, and explore innovative approaches to Cancer Therapeutics.

By bringing together experts from academia, industry, and clinical practice, we aim to accelerate the development and adoption of novel cancer therapeutics, improve diagnostic techniques, and ultimately enhance patient outcomes. The conference will cover a wide range of topics, from fundamental research to clinical applications, with a particular emphasis on emerging technologies and personalized medicine approaches.

## **CALL FOR POSTER PRESENTATIONS**

Cancer NEXT 2024 invites to submit your abstracts for poster presentations to be showcased at the upcoming conference. This is an ideal platform for sharing your groundbreaking research and innovations in the field of cancer biology, diagnosis & therapeutics.

#### **Awards for Excellence:**

Best Poster Presentations: Five exceptional posters will be awarded a
 cash prize of ₹50,000 each. These awards are designed to recognize and
 promote outstanding research contributions. Awards will be decided by
 a jury on the day of the conference, ensuring a fair and commendable
 selection.

#### **Submission Process:**

- Registration Required: To participate in the poster presentations, please ensure you are registered for the conference. Registration can be completed on our conference webpage(<a href="https://www.biofaba.org.in/CancerNext-2024.php">https://www.biofaba.org.in/CancerNext-2024.php</a>)
- Where to Submit: After registering, submit your abstracts through this google form <a href="https://forms.gle/neaUVKZXt2QVcmHp8">https://forms.gle/neaUVKZXt2QVcmHp8</a>
- Abstract Size: Maximum 250 words, Times New Roman, Font size 12, 1.5 line spacing
- Key Dates: Submission Deadline: 25th November 2024
- Late submissions may not be eligible for awards

### **Poster Specifications:**

- Size: Each poster must adhere to the A0 size (841 x 1189 mm) in portrait orientation.
- Content: Posters should include the title, list of authors with affiliations, and a structured layout that covers a brief abstract, aims, methods, results, and conclusions.
- Important Note: Presenters are responsible for printing and bringing their own posters.

#### **Presentation:**

- Posters will be displayed throughout the duration of the conference.
- Presenters are required to be available to discuss their work with conference attendees during designated times.

For Technical Queries, write us to cancernext2024@gmail.com

# **PROGRAMME**

Time	Session	Speaker/Details				
8:30 - 9:00	Registrations					
Session 1: Welcome and Introductory Remarks						
9:00 - 9:15	Welcome & Introductions	Prof. Pallu Reddanna, Executive President, Federation of Asian Biotech Associations (FABA)  Dr. Uday Saxena, CHAIR - Product Development Committee, Bharat Advanced Therapeutics  Prof. Bheerappa Nagari Director, Nizam's Institute of Medical Sciences				
		(NIMS)				
Session 2: Discovery Research Chairs: Dr. Ajith Kamath, EC Member, FABA; Dr. M Sreenivasulu, Director, MNJ Hospital						
9:15 - 9:30	Orally Deliverable and SMART Clinical Stage Oral Drug for Acute and Chronic Myeloid Leukemia	Dr. Sreedhara Voleti, COO, BAT				
9:30 - 9:45	ADC (Antibody Drug Conjugates)	Dr. Smruthi Suryaprakash, Partner, BCG				
9:45 - 10:00	Bispecific Antibodies	Dr. Murali Ramachandra, CEO, Aurigene Oncology				
10:00 - 10:15	CDK1 and TDp tyrosyl DNA Phoshodiesterase	Dr. Benubrata, Professor, Indian Association for Cultivation of Science				
10:15 - 10:30	Making Sense of Mis-sense and Non- sense: Evaluating Mis-localized Tumor Suppressors for Anti-cancer Therapy	Dr. Murali Dharan Bashyam, Head, Lab of Molecular Oncology, CDFD				
10:30 - 10:45	Hsp90 Inhibitors as Anticancer Agents: Eminence and Repercussions	Dr. A S Sreedhar, Chief Scientist, CCMB				
10:45 - 11:00	Break - Poster Presentations & Networking					
Session 3: Diagnostics & Clinical Trials Chairs: Dr. Suraj Bhansali, Director of Clinical Development, Elanco ; Dr. Roshni Paul, Professor & Head, Department of Pathology, NIMS						
11:00 - 11:15	Invitro Molecular Diagnostics - Therapeutic Targets	Dr. Sudha S Murthy, Director Pathologist, Yoda Labs				
11:15 - 11:30	Al for Oncology	Dr. Suneel Kumar BVS, Founder & CEO, Atomicas Al				
11:30 - 11:45	Microfluidics for Cancer Diagnostics	Dr. Jagan Mohan Reddy, Founder, UR Advanced Therapeutics				
11:45 - 12:00	Clinical Trials	Dr. Manmohan Acharya, General Manager, Oncova Therapeutics				

# PROGRAMME

12:00 - 12:15	Harnessing precision medicine in cancer research	Mr. Sarvepalli Bharat, Vice President, Karkinos Healthcare			
12:15 - 12:30	Exosomes Unleashed: Transforming Cancer Diagnosis Without Invasive Tests.	Dr. Sashidhar, CSO, Apollo Hospitals Educational & Research Foundation (AHREF)			
12:15 - 13:15	Lunch Break				
Chairs: Dr. Sur	ncer Therapeutics nil Kumar Manna, Head Lak shmi, Additional Professor	o of Immunology, CDFD r, Department of Medical Oncology, NIMS			
13:30 - 13:45	Gene Therapy	Dr. Murali Tummuru, Director, Virchow Biotech			
13:45 - 14:00	Cervical Cancer Vaccine	Dr. Hitt Sharma, Mr. Harish, Serum Institite of India			
14:00 - 14:15	CAR-T Cell research	Dr. Rajaram Iyer*, Executive Vice President, Laurus Labs			
14:15 - 14:30	PDX and PDO model	Dr. Suresh Poosala, Founder, Oncoseek Bio			
14:30 - 14:45	Nanotech Based Drug Delivery	Prof. Avinash Bajaj, Laboratory of Nanotechnology and Chemical Biology, Regional Center for Biotechnolgy			
14:45 - 15:15	Break - Poster Presentations & Networking				
Session 5: Rou	und Table - Discovery & De	evelopment of Therapeutics			
	. Uday Saxena, CHAIR - Pr	evelopment of Therapeutics oduct Development Committee, BAT;			
Moderator: Dr Executive Sec	. Uday Saxena, CHAIR - Pr				
Moderator: Dr Executive Sec Panelists: 15:15 - 16:15	Roundtable on Discovery & Development of	1. Dr. Ramprasad, CEO, Medgenome 2. Dr. Prashanth Bhavar, Founder, Vegen Therapeutics 3. Prof. Manavathi Bramhanandam, Department of Biochemistry, University of Hyderabad 4. Dr. Srinivas Maddi, MD, Acubiosys, 5. Mr. Raj K Shirumalla, Mission Director, Program Managemen Unit - National Biopharma Mission 6. Prof. Sadashivudu G, Medical Oncology, NIMS 7. Prof Sameer Bakhshi, AIIMS New Delhi			
Moderator: Dr Executive Sec Panelists: 15:15 - 16:15	Roundtable on Discovery & Development of Therapeutics  gnostics and Detection of Raghunadha Rao Diguma	1. Dr. Ramprasad, CEO, Medgenome 2. Dr. Prashanth Bhavar, Founder, Vegen Therapeutics 3. Prof. Manavathi Bramhanandam, Department of Biochemistry, University of Hyderabad 4. Dr. Srinivas Maddi, MD, Acubiosys, 5. Mr. Raj K Shirumalla, Mission Director, Program Managemen Unit - National Biopharma Mission 6. Prof. Sadashivudu G, Medical Oncology, NIMS 7. Prof Sameer Bakhshi, AIIMS New Delhi			
Moderator: Dr Executive Sec Panelists: 15:15 - 16:15 Session 6: Dia Moderator: Dr & Regional Ca	Roundtable on Discovery & Development of Therapeutics  gnostics and Detection of Raghunadha Rao Diguma	1. Dr. Ramprasad, CEO, Medgenome 2. Dr. Prashanth Bhavar, Founder, Vegen Therapeutics 3. Prof. Manavathi Bramhanandam, Department of Biochemistry, University of Hyderabad 4. Dr. Srinivas Maddi, MD, Acubiosys, 5. Mr. Raj K Shirumalla, Mission Director, Program Managemen Unit - National Biopharma Mission 6. Prof. Sadashivudu G, Medical Oncology, NIMS 7. Prof Sameer Bakhshi, AIIMS New Delhi			

## **TOPICS**

- Small Molecule Research
- Antibody Drug Conjugates (ADC)
- Gene Therapy Advances
- Cancer Vaccine Research
- CAR-T Cell Research
- CDK1 and TDp Tyrosyl DNA Phosphodiesterase Inhibitors
- Nanotechnology in Drug Delivery

## **REGISTRATION FEES**

Students: 1,000 INRFaculty: 3,000 INR

• Industry participants: 5,000 INR

## **REGISTRATION LINK:**

# https://biofaba.org.in/cancer\_program.php



SPONSORSHIP DETAILS	Company logo in promotions	Promotional Items in the Kit	Complementary Registrations
• Platinum - 3,00,000 INR	<b>✓</b>	<b>✓</b>	10
• Gold - 2,00,000 INR	<b>✓</b>	<b>✓</b>	5
• Silver - 1,00,000 INR			3

Bank Account Details: Federation of Asian Biotech Associations, Indian Overseas Bank, Rajbhavan Road Account number 118001000010387, Savings Bank, IFSC Code IOBA0001180, MICR Code 500020016, BSR Code 0271173, Bank Address R.V.S. Kamala Castle, Raj Bhavan Road, Somajiguda, Hyderabad 500082

(\*Donations are exempted from paying income tax upto 50% under Section 80(G) of Income Tax Act)

Please note that GST will be charged additionally on the sponsorship amount.

For more sponsorship and other information, please write to us at info@biofaba.org.in.